Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2025 09:00 ET | Source: Bluum

Bluum Unveils 17,000 Sq Ft Phoenix Facility

Bluum, North America’s Largest EdTech Provider Reimagines Workspace for Collaboration.
November 07, 2025 09:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics Presents Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study at SITC 2025 40th Anniversary Annual Meeting

− Demonstrates PPARG inhibition as a potential strategy to overcome immune resistance in advanced UC − Supports the planned Phase 1 cohort of FX-909 in combination with pembrolizumab; initiating in...
November 07, 2025 09:00 ET | Source: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor...
November 07, 2025 09:00 ET | Source: Zhejiang Apollo Sports Technology Co., Ltd.

RFN's SX-E60: A New Era of Control in Electric Off-Roading Explored at EICMA Roundtable

In conjunction with the unveiling of the SX-E60, RFN hosted an insightful roundtable discussion at EICMA titled "Beyond Performance, Infinite Control."
November 07, 2025 09:00 ET | Source: T-knife Therapeutics

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing --TK-6302 Clinical Trial Application planned in...
November 07, 2025 09:00 ET | Source: Coherus Oncology, Inc.

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114...
November 07, 2025 09:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant...
November 07, 2025 09:00 ET | Source: IT Nation

Strategy Overview Named Champion of PitchIT Competition at IT Nation Connect 2025

TAMPA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- IT Nation, a global community of peers, thought leaders, and experts dedicated to elevating the IT ecosystem to new heights, announced today at its...
November 07, 2025 09:00 ET | Source: BioAge Labs, Inc.

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...
November 07, 2025 09:00 ET | Source: IO Biotech

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the SITC 2025 Annual Meeting